BACKGROUND: Mantle cell lymphoma (MCL) is a chronically relapsing malignancy with deregulated cell cycle progression. We analyzed efficacy, mode of action, and predictive markers of susceptibility to palbociclib, an approved CDK 4/6 inhibitor, and its combination with venetoclax, a BCL2 inhibitor. METHODS: A panel of nine MCL cell lines were used for in vitro experiments. Four patient derived xenografts (PDX) obtained from patients with chemotherapy and ibrutinib-refractory MCL were used for in vivo proof-of-concept studies. Changes of the mitochondrial membrane potential, energy-metabolic pathways, AKT activity, and pro-apoptotic priming of MCL cells were evaluated by JC-1 staining, Seahorse XF analyser, genetically encoded fluorescent AKT reporter, and BH3 profiling, respectively. MCL clones with gene knockout or transgenic (over)expression of CDKN2A, MYC, CDK4, and RB1 were used to estimate impact of these aberrations on sensitivity to palbociclib, and venetoclax. RESULTS: Co-targeting MCL cells with palbociclib and venetoclax induced cytotoxic synergy in vitro and in vivo. Molecular mechanisms responsible for the observed synthetic lethality comprised palbociclib-mediated downregulation of anti-apoptotic MCL1, increased levels of proapoptotic BIM bound on both BCL2, and BCL-XL and increased pro-apoptotic priming of MCL cells mediated by BCL2-independent mechanisms, predominantly palbociclib-triggered metabolic and mitochondrial stress. Loss of RB1 resulted in palbociclib resistance, while deletion of CDKN2A or overexpression of CDK4, and MYC genes did not change sensitivity to palbociclib. CONCLUSIONS: Our data strongly support investigation of the chemotherapy-free palbociclib and venetoclax combination as an innovative treatment strategy for post-ibrutinib MCL patients without RB1 deletion.

1st Department of Internal Medicine Hematology 1st Faculty of Medicine General University Hospital Charles University Prague Czech Republic

BIOCEV LF1 Biotechnology and Biomedicine Centre 1st Faculty of Medicine Charles University Prague Czech Republic

Department of Experimental Biology Faculty of Science Palacky University Olomouc Olomouc Czech Republic

Faculty of Informatics and Statistics Prague University of Economics and Business Prague Czech Republic

Institute of Biotechnology Czech Academy of Sciences Prague Czech Republic

Institute of Molecular Genetics Czech Academy of Sciences Prague Czech Republic

Institute of Pathological Physiology 1st Faculty of Medicine Charles University Prague Czech Republic

Integrated Research Center in Immunology and Oncology CRCI2NA Nantes University Nantes France

Laboratory of Growth Regulators Palacky University Olomouc and Institute of Experimental Botany The Czech Academy of Sciences Olomouc Czech Republic

Zobrazit více v PubMed

Wang K, et al. Cell cycle dysregulation in Mantle Cell Lymphoma: Genomics and Therapy. Hematol Oncol Clin North Am. 2020;34(5):809–23. doi: 10.1016/j.hoc.2020.05.003. PubMed DOI PMC

Silkenstedt E, Linton K, Dreyling M. Mantle cell lymphoma - advances in molecular biology, prognostication and treatment approaches. Br J Haematol. 2021;195(2):162–73. doi: 10.1111/bjh.17419. PubMed DOI

Davids MS, et al. Phase I first-in-human study of Venetoclax in patients with relapsed or refractory Non-hodgkin Lymphoma. J Clin Oncol. 2017;35(8):826–33. doi: 10.1200/JCO.2016.70.4320. PubMed DOI PMC

Eyre TA, et al. Efficacy of venetoclax monotherapy in patients with relapsed, refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor therapy. Haematologica. 2019;104(2):e68–71. doi: 10.3324/haematol.2018.198812. PubMed DOI PMC

Clark AS, et al. Palbociclib (PD0332991)-a selective and potent cyclin-dependent kinase inhibitor: a review of Pharmacodynamics and Clinical Development. JAMA Oncol. 2016;2(2):253–60. doi: 10.1001/jamaoncol.2015.4701. PubMed DOI

Leonard JP, et al. Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma. Blood. 2012;119(20):4597–607. doi: 10.1182/blood-2011-10-388298. PubMed DOI

Che Y, et al. Dual targeting of CDK4/6 and Bcl-2 exhibits a potent antitumor effect on mantle cell lymphoma. Blood Adv. 2023;7(14):3361–5. doi: 10.1182/bloodadvances.2022008954. PubMed DOI PMC

O’Leary B, et al. The Genetic Landscape and Clonal evolution of breast Cancer Resistance to Palbociclib plus Fulvestrant in the PALOMA-3 trial. Cancer Discov. 2018;8(11):1390–403. doi: 10.1158/2159-8290.CD-18-0264. PubMed DOI PMC

Malorni L, et al. A gene expression signature of retinoblastoma loss-of-function is a predictive biomarker of resistance to palbociclib in breast cancer cell lines and is prognostic in patients with ER positive early breast cancer. Oncotarget. 2016;7(42):68012–22. doi: 10.18632/oncotarget.12010. PubMed DOI PMC